NCT02004522 · OUTCOME

Lymph Node Response Rate

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) · Source last updated 2023-09-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Lymph node response defined as greater than or equal to 50% decrease in the SPD of target lymph nodes

Analysis population: Intent to Treat

Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.

Ofatumumab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Duvelisib	160
Ofatumumab	159

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Duvelisib	136	Not reported	Not reported	Not reported	Not reported
Ofatumumab	25	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Lymph node response defined as greater than or equal to 50% decrease in the SPD of target lymph nodes

groups

param Type

COUNT_OF_PARTICIPANTS

population Description

Intent to Treat

reporting Status

POSTED

time Frame

3 years

title

Lymph Node Response Rate

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice